Flunarizine is a selective calcium-entry blocker used as migraine prophylaxis in patients with severe and frequent episodes who have not responded adequately to more common treatments. Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity.
- Mechanism
- Curator reviewed
Flunarizine inhibits the influx of extracellular calcium through myocardial and vascular membrane pores by physically plugging the channel. The decrease in intracellular calcium inhibits the contractile processes of smooth muscle cells, causing dilation of the coronary and systemic arteries, increased oxygen delivery to the myocardial tissue, decreased total peripheral resistance, decreased systemic blood pressure, and decreased afterload.
- Primary indication
- Used in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of epilepsy.Curator reviewed · 1 structured indication
- Formula / weight
- C26H26F2N2 · 404.4948 g/mol (avg)
- First approval
- Canada, 1997
Resolves to
SMANXXCATUTDDT-QPJJXVBHSA-NSMILESFC1=CC=C(C=C1)C(N1CCN(C\C=C\C2=CC=CC=C2)CC1)C1=CC=C(F)C=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Flunarizine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account